Evaluation of Pharmacokinetic Interactions between Levonorgestrel Vaginal Delivery System and Miconazole in Healthy Female Subjects

The primary objective of this study is to evaluate the **drug-drug interactions** between the Levonorgestrel Vaginal Delivery System (LVDS) and Miconazole in healthy female participants. Understanding these interactions is clinically relevant as it may impact the efficacy and safety of the LVDS when used concurrently with Miconazole, a common antifungal medication. This investigation is crucial for ensuring optimal therapeutic outcomes and minimizing potential adverse effects in patients using these medications simultaneously.

The clinical trial involves a **study population** consisting exclusively of female participants, with an age range categorized as 3, which typically corresponds to adults aged 18 to 65 years. The trial does not focus on any specific **medical condition**, as indicated by the absence of a defined condition. The sponsor has not provided information regarding the total number of participants. The trial population was selected with consideration for vulnerable populations, although specific lifestyle considerations such as diet, physical activity, or habits have not been detailed. The sponsor has not disclosed any principal inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate **drug-drug interactions** between the **Levonorgestrel Vaginal Delivery System (LVDS)** and **Miconazole** in healthy female participants. This study is a Phase 3 trial, which is categorized as a randomized, double-blind, and controlled trial. The estimated recruitment start date is April 21, 2025, with an anticipated end date of August 12, 2025. The trial does not involve participants with any specific medical condition, as it focuses on healthy individuals.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. The trial will include multiple follow-up visits to monitor the participants' response to the treatment and to collect necessary data. These visits are crucial for ensuring participant safety and for the collection of pharmacokinetic and pharmacodynamic data. The end-of-study visit will conclude the trial, where final assessments will be conducted, and participants will be debriefed.

The expected length of participant involvement in the trial is approximately four months, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse reactions to the investigational products, non-compliance with study protocols, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 21, 2025, with an estimated completion date of August 12, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the therapeutic benefits of the intervention under investigation. The trial's design will ensure that efficacy assessments are conducted systematically throughout the study duration, although specific timepoints and tools for these assessments are not specified in the provided information.